BIND Presents Data Demonstrating Ability of Accurins to Improve Efficacy and Tolerability of Multiple Anti-Cancer Agents

BIND Therapeutics, Inc.

today reported data demonstrating the efficacy and tolerability of BIND's Accurin platform with multiple anti-cancer agents. These data, which were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston, November 5-9, 2015, describe the ability of Accurins to control the biodistribution of therapeutic payloads across multiple active anti-cancer agents, pathways and targets, which results in either improved efficacy, tolerability or both. The four posters presented include preclinical and clinical pharmacokinetic data from BIND's clinical stage Accurin compound, BIND-014; data from BIND's preclinical stage Accurin, BIND-510; and new